Holen Sie sich die Stockscreener-App
118.84
3.70%
-4.56
Handel nachbörslich:
118.85
0.010
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$123.40
Offen:
$123.89
24-Stunden-Volumen:
9.07M
Relative Volume:
1.31
Marktkapitalisierung:
$147.46B
Einnahmen:
$29.04B
Nettoeinkommen (Verlust:
$8.11B
KGV:
18.42
EPS:
6.4525
Netto-Cashflow:
$9.67B
1W Leistung:
-0.79%
1M Leistung:
+1.76%
6M Leistung:
+20.16%
1J Leistung:
+21.39%
1-Tages-Spanne:
$117.54
$124.00
1-Wochen-Bereich:
$117.54
$124.10
52-Wochen-Spanne:
$86.08
$124.61
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
118.84 | 153.26B | 29.04B | 8.11B | 9.67B | 6.4525 |
|
LLY
Lilly Eli Co
|
924.37 | 839.03B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.57 | 450.47B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.16 | 387.13B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.35 | 242.86B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
86.28 | 212.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
What analysts say about Gilead Sciences Inc stockTrading Volume Trends & Fast Growing Trading Plans - earlytimes.in
How Recent Developments Are Shaping the Gilead Sciences Investment Story - Yahoo Finance
Aviva PLC Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Identifying reversal signals in Gilead Sciences Inc.Day Trade & Safe Capital Preservation Plans - newser.com
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead stock falls after drug fails in Phase 3 breast cancer trial - Investing.com India
Gilead Sciences (GILD) Phase 3 Trial for Trodelvy Falls Short - GuruFocus
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend - Benzinga
Gilead (GILD) Phase 3 Study Results for Trodelvy in Breast Cance - GuruFocus
Gilead's breast cancer drug fails to meet main goal of late-stage study - Reuters
Gilead Trodelvy trial fails in breast cancer (GILD:NASDAQ) - Seeking Alpha
Gilead’s breast cancer drug Trodelvy fails to meet primary endpoint By Investing.com - Investing.com Canada
Gilead provides update on phase 3 ASCENT-07 study - MarketScreener
Gilead (GILD) Unveils Promising Long-term Data on Livdelzi for P - GuruFocus
Gilead Provides Update on Phase 3 ASCENT-07 Study - Business Wire
Gilead reports long-term data supporting Livdelzi for PBC patients By Investing.com - Investing.com South Africa
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression - The AI Journal
Gilead Sciences, Inc. $GILD Shares Sold by OneAscent Family Office LLC - MarketBeat
Achmea Investment Management B.V. Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Sienna Gestion Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Andra AP fonden Has $64.06 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Sprucegrove Investment Management Ltd. Sells 16,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Claro Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Why one expert thinks Gilead can produce a $25 HIV prevention shot, help eradicate the disease in the U.S. - statnews.com
Neglected & Emerging Viruses and Pandemic Preparedness - Gilead Sciences
Is Gilead Sciences Inc. still worth holding after the dip2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Key facts: Gilead's Yeztugo demand driven by therapy switches; COVID-19 shot demand drops - TradingView
Gilead Sciences, Inc. $GILD Shares Sold by First Horizon Advisors Inc. - MarketBeat
Is Gilead Sciences Inc. stock cheap at current valuationTake Profit & Fast Momentum Entry Tips - newser.com
Genus Capital Management Inc. Sells 31,653 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. stock reach all time highs in 2025Weekly Trade Report & Daily Profit Focused Screening - fcp.pa.gov.br
Trillium Asset Management LLC Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Resona Asset Management Co. Ltd. Buys 7,426 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Atlantic Union Bankshares Corp Has $20.38 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences Inc. stock is favored by top institutionsTrade Volume Report & Verified Chart Pattern Signals - fcp.pa.gov.br
How strong is Gilead Sciences Inc. stock revenue growthJuly 2025 Breakouts & Technical Entry and Exit Alerts - fcp.pa.gov.br
Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
Will Gilead Sciences Inc. stock pay special dividendsTrend Reversal & Community Trade Idea Sharing Platform - fcp.pa.gov.br
Why Gilead Sciences Inc. (Common Stock) (GIS0) stock remains stable2025 Technical Patterns & Momentum Based Trading Ideas - fcp.pa.gov.br
Chart based exit strategy for Gilead Sciences Inc.2025 Retail Activity & Stepwise Trade Execution Plans - newser.com
Price momentum metrics for Gilead Sciences Inc. explainedEarnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - sharewise.com
Applying chart zones and confluence areas to Gilead Sciences Inc.2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
A Look at Gilead Sciences (GILD) Valuation Following Upgraded Earnings Guidance and Strong Q3 Results - Yahoo Finance
Gilead’s Research Scholars Program Supports New Investigations into Rare Liver Disease - Gilead Sciences
Developing predictive dashboards with Gilead Sciences Inc. dataJuly 2025 EndofMonth & Weekly Momentum Stock Picks - newser.com
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00 at Argus - MarketBeat
Milestone Asset Management LLC Has $2.17 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by NewSquare Capital LLC - MarketBeat
J. W. Coons Advisors LLC Has $1.51 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Denies Infringing Chinese Military Body's COVID Patent - Law360
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.78%
1.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):